EP4470566A1 — Room temperature stable formulation of norepinephrine
Assigned to B Braun Melsungen AG · Expires 2024-12-04 · 1y expired
What this patent protects
The present disclosure relates to a container comprising a liquid phase and a gas phase, wherein the liquid phase is a pharmaceutical composition comprising norepinephrine, or a pharmaceutically acceptable salt thereof, a buffering system consisting of citric acid and a pharmaceu…
USPTO Abstract
The present disclosure relates to a container comprising a liquid phase and a gas phase, wherein the liquid phase is a pharmaceutical composition comprising norepinephrine, or a pharmaceutically acceptable salt thereof, a buffering system consisting of citric acid and a pharmaceutically acceptable salt thereof, at least one tonicity agent, and water; and wherein the gas phase has an oxygen content of 0.2 % (V/V) or more based on the total volume of the gas phase; and a method of manufacturing the same.
Drugs covered by this patent
- Levophed (Norepinephrine Bitartrate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.